生物谷報道：美國Roswell Park研究中心的科研人員在腫瘤綜述雜志上提出新觀點,，維生素D信號通路是潛在的抗腫瘤治療途徑之一。
維生素D代謝通路：25（OH）D3被運至腎皮質(zhì)部,，被腎臟的25-羥基維生素D3 1α-羥化酶和24-羥化酶分別羥化為1，25（OH）2D3 和24,，25（OH）2D3 ,。1，25（OH）2D3是生物活性最強的代謝物,。
流行病學(xué)調(diào)查發(fā)現(xiàn),，人類多種腫瘤的病因與維生素D缺乏有關(guān)。臨床前期研究也發(fā)現(xiàn),，活性維生素D（α25(OH)(2)D(3),，鈣三醇）及維生素D類似物有抗腫瘤作用，抑制腫瘤細胞增殖,，促進其調(diào)亡,，及抑制血管生成。此外,，鈣三醇抗腫瘤效應(yīng)還影響多種細胞毒素和抗腫瘤藥物,。
由此，研究者總結(jié)認為,，從流行病學(xué),、試驗及臨床研究，都支持維生素D及維生素D類似物具有防治腫瘤的作用,。
原始出處:
Nature Reviews Cancer 7, 684-700 (September 2007) | doi:10.1038/nrc2196
Vitamin D signalling pathways in cancer: potential for anticancer therapeutics
Kristin K. Deeb1, Donald L. Trump2 & Candace S. Johnson1 About the authors
Epidemiological studies indicate that vitamin D insufficiency could have an aetiological role in various human cancers. Preclinical research indicates that the active metabolite of vitamin D, 1,25(OH)2D3, also known as calcitriol, or vitamin D analogues might have potential as anticancer agents because their administration has antiproliferative effects, can activate apoptotic pathways and inhibit angiogenesis. In addition, 1,25(OH)2D3 potentiates the anticancer effects of many cytotoxic and antiproliferative anticancer agents. Here, we outline the epidemiological, preclinical and clinical studies that support the development of 1,25(OH)2D3 and vitamin D analogues as preventative and therapeutic anticancer agents.
Author affiliations
Departments of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, New York, USA.
Departments of Pharmacology and Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.
Correspondence to: Candace S. Johnson1 Email: [email protected]
